Corneal crosslinking shows favourable long-term outcomes

Article

Studies with follow-up of 2 to 6 years show that corneal crosslinking for progressive keratectasia is safe and induces long-term structural changes.

Data showed that CXL results in a significant keratometric flattening effect that is stable in most eyes, while causing minimal complications or significant best spectacle-corrected visual acuity (BSCVA) loss, noted Prof. Seiler, professor of ophthalmology, University of Zurich, and chairman, IROC Zurich, Switzerland.

Related Videos
Dr Adam Muzychuk discusses his ASCRS presentation
Gret Kunst, CEO of Aurion Biotech
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Greg Kunst, CEO of Aurion Biotech
Trukera Medical rebranding ushers in new era of expansion into cornea market
Related Content
A pair of eyeglasses melting. Generated with Canva AI.

An alternative approach to spectacle independence

March 22nd 2024
Article

Laser blended vision is a proven modality for presbyopia treatment, but its principles can be reproduced with EDOF IOLs

The Helix Nebula, also known as the God's Eye Nebula. Image credit: ©Supernova – stock.adobe.com

Surgical taming of neurotrophic keratopathy: From amniotic membrane grafting to neurotisation

March 5th 2024
Article

Clara Chan, MD, shares surgical pearls for neurotrophic keratopathy and explores new pathways through neurotisation

The cover of "Modern Keratoplasty: Surgical Techniques and Indications" next to an image of an eye. Book cover image used with permission from Springer Nature. Cornea image credit: ©Zarina Lukash – stock.adobe.com

Book excerpt: Rescuing failed penetrating keratoplasty grafts

February 28th 2024
Article

Penetrating keratoplasty remains a popular choice for certain patients

A woman pinches the bridge of her nose, indicating pain, and the image shows her brain lit up in red detail. Image credit: ©Thongden_studio – stock.adobe.com

US FDA grants OKYO Pharma approval of IND for neuropathic corneal pain therapy OK-101

February 9th 2024
Article

The company, headquarted in New York and London, named OK-101 as the first IND clearance granted by the FDA for a drug to begin clinical studies specifically to treat NCP

A doctor reviews paperwork with a woman. Image credit: ©Drazen – stock.adobe.com

Corneas harvested from patients who died of drowning are viable for transplantation

January 23rd 2024
Article

Postoperative outcomes of the tissues obtained from these donors were satisfactory

A person's hand moves a sliding counter from 2023 to 2024. Image credit: ©Dilok – stock.adobe.com

Next-gen lasers and IOLs for every patient: the year ahead in cornea

December 14th 2023
Article

Why “acceleration” is the industry keyword for 2024

© 2024 MJH Life Sciences

All rights reserved.